With a view to increase production capacity, the Department of Pharmaceuticals has approved projects to establish bulk drug parks in Bharuch district of Gujarat, Una district of Himachal Pradesh and Anakapalli district of Andhra Pradesh under its scheme for Promotion of Bulk Drug Parks, and medical parks in Greater Noida district of Uttar Pradesh, Ujjain district of Madhya Pradesh and Kanchipuram district of Tamil Nadu under its scheme for Promotion of Medical Device Parks. Currently, these projects are at various stages of execution.

The details regarding the PLI schemes being implemented by the Government, including the details of success achieved as a result of their implementation, are as follows:

1. Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India (also known as PLI scheme for Bulk Drugs): The scheme is aimed at avoiding disruption in supply of critical APIs used to make critical drugs for which there are no alternatives by reducing supply disruption risk due to excessive dependence on single source. The scheme has a budgetary outlay of ₹6,940 crore. Till September 2025, investment of ₹4,763.34 crore has already been made in three and a half years of scheme production period, against an investment commitment of ₹4,329.95 crore over the period of six years in greenfield projects. Further, production capacities have been created for 26 KSMs/DIs/APIs, which were earlier primarily imported. The scheme has resulted in cumulative sales of ₹2,315.44 crore reported till September 2025, including exports of ₹508.12 crore, thereby avoiding imports worth ₹1,807.32 crore.
2. PLI Scheme for Pharmaceuticals: The scheme is aimed at enhancing India’s manufacturing capabilities by increasing investment and production in the pharmaceuticals sector and contributing to product diversification to high-value goods in the pharmaceutical sector and incentivises production of high-value medicines such as biopharmaceuticals, complex generic drugs, patented drugs or drugs nearing patent expiry, auto-immune drugs, anti-cancer drugs, etc. as well as production of KSMs/DIs/APIs other than those notified under the PLI Scheme for Bulk Drugs. It has a budgetary outlay of ₹15,000 crore. As of September 2025, the committed investment of ₹17,275 crore targeted over the six-year period of the scheme stands substantially exceeded with cumulative investment of ₹40,890 crore made in three and a half years of scheme production period in both brownfield and greenfield projects. Further, cumulative sales of eligible products worth ₹3,15,492 crore have been made under the scheme, including exports worth ₹2,02,724 crore. Cumulative domestic sales of KSMs/DIs/APIs produced under the scheme till September 2025 is worth ₹26,123 crore and thereby contributing to import avoidance. Further, 726 KSMs/DIs/APIs are being manufactured under the scheme, including 191 which have been manufactured for the first time under the scheme.

The Department of Commerce has informed that the Export Promotion Mission, announced in the Union Budget 2025-26, aims to provide comprehensive support to exporters, including those in pharmaceuticals. Under this, “Niryat Protsahan” will improve access to affordable trade finance for exporters, while “Niryat Disha” will support export-readiness through non-financial enablers such as compliance and capacity-building. This will be implemented through a fully digital platform of the Directorate General of Foreign Trade.

This information was given by Union Minister of State in the Ministry of Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in Rajya Sabha today.

******

PC/NK/PM

 

(रिलीज़ आईडी: 2200939) आगंतुक पटल : 319